ABCG2 rs2231142 and NR1I2 rs2472677 influence dolutegravir concentrations in plasma. by Elliot, Emillie et al.
BACKGROUND 
Dolutegravir (DTG) is a preferred agent in most guidelines but concerns are 
emerging as real life data show higher rates of neuropsychiatric adverse events 
(NP-AEs) than seen in licensing trials. Supra-therapeutic drug concentrations 
may predispose to side effects, amongst other factors. An association between 
the ABCG2 genetic variant and DTG plasma peak concentrations has been 
shown, whilst an association between carrying UGT1A1*6 and/or UGT1A1*28, 
DTG trough concentrations and selected NP-AEs has been made by some and 
refuted by others.2-3 The objectives of our study was to investigate the 
association between pharmacogenetic variants of the following genes linked to 
DTG transport and metabolism and DTG pharmacokinetic (PK) parameters: 
UGT1A1, ABCG2, NR1I2 and CYP3A. 
 
METHODS  
•  Pooled data from six Phase I and III clinical studies was analyzed in subjects 
receiving 50 mg DTG once daily (and no interacting co-medications) after formal 
consent to a pharmacogenetic sub-study. 
•  Subjects underwent intensive PK sampling and steady-state plasma 
concentrations were determined using validated LC-MS/MS or UPLC.4-6 
•  Genomic DNA was extracted from whole blood using a spin-column based kit 
(Omega bio-tek). 
•  UGT1A1*6, UGT1A1*27, ABCG2, NR1I2 and CYP3A were genotyped using 
PCR-based allelic discrimination Taqman assays. The UGT1A1 promoter region 
(*1, *28, *36 and *27) was genotyped using an Agena MassArray iPLEX assay.  
•  Variables were tested for normal distribution using the Shapiro-Wilkes test 
and were log10 transformed where required.   
•  Associations between subject characteristics or genotypes and DTG PK 
parameters (logCmin, Cmax and AUC0-24) were determined through univariate and 
multivariate linear regressions. Univariate linear regressions with a P value of 
≤0.2 were carried through to multivariate linear regression analysis where a P 
value of ≤0.05 was classed as statistically significant.  
RESULTS 
•  95 subjects were included (59 HIV-infected and 36 healthy volunteers; 68 men 
and 27 women). Characteristics and genotypes are summarised in table 1.  
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•  ABCG2	 (rs2231142)	 and	NR1I2 (rs2472677) variants were both independently 
associated with higher DTG plasma	 peak	 concentraFons	 (P=0.047,	 β=0.053	 and	
P=0.033,	β=0.032),	as	were	ethnicity	and	accompanying	drugs.	Weight	and	height	were	
inversely	 	 associated	 with	 Cmax.	 The	NR1I2 (rs2472677) variant was additionally 
associated with an  increase in total DTG exposure (P=0.011,	β=5698)	(tables	2	and	
3,	figure	1).		
•  Importantly,	 the	 above	 geneFc	 associaFons	 were	 persistently	 observed	 when	 the	
analyses	were	restricted	to	Caucasians	only.		
















and	AUC,	which	 could	 suggest	a	 complex	metabolic	 influence,	 through	 the	PXR	 intra-
nuclear	receptor.	Our	results	also	confirm	the	associaFon	between	ABCG2	421C>A	and	
Cmax	alone,	which	may	signal	an	impact	on	DTG	absorpFon.	Further	research	in	bigger	
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 Total N 
95 
Median (IQR) 
Age (years) 51 (35-64) 
Weight (kg) 76.8 (66.6-84.3 
Height (cm) 173 (167-177) 
ARV Regimen N (%) 
• ABC/FTC/DTG 40 (42) 
•  TFV/3TC + DTG 19 (20) 
• DTG alone 36 (38) 
Ethnicity N (%) 
• Caucasian  71 (75) 
• Black 16 (17) 
• Asian 4 (4) 
• Mixed race 1 (1) 
• Other 3 (3) 
Female gender 26 (27) 
DTG GM Cmax 3974 ng/mL 
DTG GM Cmin 1054 ng/mL 
DTG GM AUC0-24 51846 hr*ng/mL 





(*1/*28 or *1/*37) 
Low activity 
(*28/*28 or *37/*37) 
41 45 14 
UGT1A1*6 (rs4148323) *1/*1 *1/*6 *6/*6 100 64 0 
UGT1A1*27 (rs35350960) *1/*1 *1/*27 *27/*27 100 0 0 
CYP3A4*22 (rs35599367) GG GA AA 88 6 5 
CYP3A5*3 (rs776746) TT TC CC 12 12 77 
ABCG2 421 C>A (rs2231142) CC CA AA 82 17 1 
ABCG2 34 C>T (rs2231137) CC CT TT 0 17 83 
NR1I2 63396 C>T (rs2472677) CC CT TT 17 43 40 
NR1I2 44477 A>G (rs1523130)  TT CT CC 19 39 42 
Log10 Cmax 
Univariate Linear Regressions Multivariate Linear Regressions 
P value β value (95% CI) r2 P value β value (95% CI) r2 
Log10Height (Log10cm) 0.008 -1.716 0.092 0.012 -1.649 0.394 
Weight (kg) 0.000 -0.004 0.175 0.009 -0.003 0.394 
Ethnicity 0.297 0.002 0.015       
ARV regimen 0.019 0.061 0.071 0.001 0.074 0.394 
ABCG2 421 C>A (rs2231142) 0.111 0.050 0.034 0.047 0.053 0.394 
NR1I2 63396 C>T (rs2472677) 0.010 0.045 0.086 0.033 0.032 0.394 
Log10 Cmin 
Univariate Linear Regressions Multivariate Linear Regressions 
P value β value (95% CI) r2 P value β value (95% CI) r2 
UGT1A1*28 (rs8175347) 0.153 -0.101 0.027 0.153 -0.101 0.027 
AUC0-24 
Univariate Linear Regressions Multivariate Linear Regressions 
P value β value (95% CI) r2 P value β value (95% CI) r2 
Log10Height (Log10cm) 0.025 -184350.5 0.066 0.622 -51210.2 0.329 
Weight (kg) 0.009 -348.9 0.088 0.007 351.2 0.283 
Ethnicity 0.005 814.3 0.1 0.002 934.2 0.283 
UGT1A1*28 (rs8175347) 0.112 4407.3 0.042 0.240 2965.9 0.322 
CYP3A4*22 (rs35599367) 0.057 5909.5 0.048 0.195 3592.6 0.304 
CYP3A5*3 (rs776746) 0.140 -3374.7 0.030 0.603 1591.8 0.326 
NR1I2 63396 C>T (rs2472677) 0.053 4324.7 0.050 0.011 5698.0 0.283 
ABCG2 421 C>A (rs2231142) % difference between wild 
type and SNP variant CC CA AA 
GM (95%CI) Cmax (ng/mL) 3893 (3659-4126) 4346 (3395-5297) 4994 (n=1) Heteroz. 12% 
Homoz. 
28% 
NR1I2 63396 C>T (rs2472677) % difference between wild 
type and variant SNP CC CT TT 
GM Cmax (95%CI) (ng/mL) 3445 (3095-3836) 3938 (3540-4382) 4278 (3920-4668) Heteroz. 14% Homoz. 24% 




(49473-58867) Heteroz. 27% 
Homoz. 
27% 
Table	2:	Univariate	linear	regression	(P=≤0.2)	completed,	all	staFsFcally	significant	results	then	carried	through	to	mulFvariate	
linear	regression	analysis	(P=≤0.05).	StaFsFcally	significant	associaFons	are	shown	in	bold.		
Table	3:	Dolutegravir	(DTG)	pharmacokineFc	parameters	(GM,	95%CI),	summarized	by	associated	genotypic	variant.	
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